3. Results

Patient demographics are summarized in Table 1. Three patients stopped memantine because of lack of apparent efficacy (N= 1), loss to follow-up (N= 1), and combined lack of efficacy/AE (N= 1, early awakening with confusion, hallucinations). The 9 analyzed patients, 5 male (55.6%), ages 53.5±20.8 years, with 50.3±16.5 CAG repeats, were titrated to the maximum dose of 20 mg of memantine, and followed for 3.8±1.0 months. A significant difference existed between their initial (x= 49.3±21.3) and final (x= 39.0±17.0) total UHDRS motor scores (P= 0.008), mostly due to a significant (P= 0.008) decrease in their maximum chorea rating at their final visit (11.5±6.3 to 4.8±3.8)(Table 2) Patients did not show a significant change in their cognitive (P= 0.625) or behavioral (P= 0.258) ratings. Their total functional capacity (P= 0.078) and independence scale rating (P= 1.000) also failed to show a significant change. Adverse events were mild and infrequent: one patient reported drowsiness and one complained of worsening balance, speech and social interaction. No serious adverse events were reported.